Why sue, FDA asks Amarin: You can spread the word on Vascepa already

FDA's Janet Woodcock

Pharma marketers are closely watching Amarin's ($AMRN) lawsuit demanding the right to talk up off-label uses for its cardiovascular drug Vascepa. After all, if the legal attack against FDA regulations succeeds, that gives credence to drugmakers' free speech argument--and could open up new worlds of drug promotion. The FDA knows this. And it's fighting back, if obliquely. Report

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.